Lung cancer and immunotherapy: why it stops working, and how macrophages are involved
Macrophages have been the core subject for most of my working life, and what has kept me on them is how we keep discovering new ways in which they shape biological processes, in both health and disease. They are not one cell type with one job. They read their surroundings and behave accordingly, which is why they turn up in so many different disease processes.
Through that work, in our own group and in many others, something has become increasingly difficult to ignore: macrophages may also play an important role in why cancer treatments stop working.
That question is most interesting in immunotherapy. Checkpoint inhibitors have changed what is possible in lung cancer, but many patients do not respond to them. In others, the treatment works at first and then the disease starts to progress again.
November is Lung Cancer Awareness Month. It is therefore a good moment to take a closer look at one of the questions that interests us most: why does immunotherapy stop working, and what role might macrophages play in that resistance?
When immunotherapy stops working
Checkpoint inhibitors represented a major advance in cancer treatment because they showed what could be achieved by enabling the patient’s own immune system to recognize and attack cancer.
But for patients who do not benefit, broadly two different things can happen. Some never respond at all. Others respond, sometimes for a long time, and then the disease starts growing again.
The biology behind the two is not necessarily the same, and they probably do not have the same solution. The second, known as acquired resistance, is the one this post is about.
Cancer is not static. It evolves under the pressure of treatment and can find new ways to avoid immune attack. So to understand resistance, we have to look beyond the cancer cells themselves and at the environment in which the tumor is growing.
The macrophage connection
Tumors do not simply hide from the immune system. They can actively reshape the immune environment around them.
Under normal circumstances, a macrophage’s ability to respond to its surroundings is one of its strengths. Signals from the tissue tell macrophages what is happening and what they need to do. But cancer can exploit that same flexibility.
We know that macrophages are among the most abundant immune cells recruited into many tumors. Rather than supporting an effective immune response, some of these macrophages can be reprogrammed by the tumor to suppress that response instead. They become part of an environment in which the cancer is better able to survive, grow and evade immune attack.
Checkpoint inhibitors can remove an important brake on the immune response. But our hypothesis is that if other parts of the tumor environment continue to actively suppress that response, removing that brake is not enough.
“In cancer treatment, a single method usually does not solve it. Combinations and many kinds of treatment are needed.”
Why combinations matter
This is also why I do not think there is a single switch behind resistance.
Earlier this month I had the opportunity to discuss lung cancer immunotherapy on Huomenta Suomi, on Finnish MTV3, with oncologist Juha Kononen of Docrates Mehiläinen. He put the clinical reality very simply: “In cancer treatment, a single method usually does not solve it. Combinations and many kinds of treatment are needed.“
That observation gets to an important part of the problem. Cancer can use multiple mechanisms to survive. A treatment may address one of them while others remain.
And that raises a question: if immunosuppressive macrophages are one part of the environment that allows cancer to resist immune attack, could targeting them alongside checkpoint inhibition help overcome that resistance?
Testing that question in BLAZE
BLAZE is a Phase 1/2 investigator-initiated trial led by The Institute of Cancer Research, London, in collaboration with The Royal Marsden NHS Foundation Trust. The investigators are evaluating bexmarilimab in combination with the PD-1 inhibitor nivolumab in patients with metastatic non-small cell lung cancer or melanoma whose disease has progressed following prior anti-PD-1-based immunotherapy. We announced in October 2026 that the first patient had been dosed in the trial.
What interests me as a macrophage biologist is the setting. These patients have already received checkpoint inhibition. The study is therefore asking a very specific question in a treatment-resistant setting: can targeting immunosuppressive macrophages alongside PD-1 inhibition help restore an effective anti-tumor immune response?
BLAZE is an early-stage study. It will evaluate the safety and tolerability of the combination as well as early signs of anti-tumor activity. It will not answer every question about this approach, nor should we expect it to. But it gives us an opportunity to test whether the biology we have been studying can translate into a setting where immunotherapy has stopped working.
And that question matters beyond lung cancer. Acquired resistance to immunotherapy is a challenge across multiple tumor types.
The biology underneath the question
Of course, this leaves a much bigger set of questions underneath.
Why do macrophages become immunosuppressive in the first place? What allows a tumor to change how they behave? Can that behavior be changed? And if it can, what happens elsewhere in the immune system?
More than two decades of research on the macrophage receptor Clever-1, and the development of bexmarilimab, have answered parts of these questions and sharpened the rest.
For now, Lung Cancer Awareness Month is a useful reminder that progress in cancer treatment is not only about finding new ways to attack cancer cells. It is also about understanding why a treatment that works well can later stop working, and what the rest of the tumor environment has to do with that.
If you would like to watch the episode of Huomenta Suomi where we discussed these questions, it is available in Finnish: Voiko elimistön opettaa taistelemaan keuhkosyöpää vastaan?
— Maija Hollmén, Chief Scientific Officer
Forward-looking statements: This post contains forward-looking statements regarding the development of bexmarilimab and the BLAZE trial. Bexmarilimab is investigational and has not been approved by any regulatory authority.